A Phase 1/2 interventional study of Propranolol Hydrochloride and Placebo in Postoperative Chylothorax, Congenital Heart Disease and Open Heart Surgery, sponsored by June Wu. Recruiting at 1 site in United States. Open to participants aged 7 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by June Wu · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 356 studies in Heart Defects, Congenital with a site in United States — 67 open to participants now, 87 under way, 4 of them phase 3. Heart Defects, Congenital · United States.
Among the 356 studies in Heart Defects, Congenital with a site in United States, this one is the 86th largest by planned enrollment of the 184 interventional ones that give a count, is one of 13 that started in 2025, is one of 8 in phase 1/2, reaches primary completion later than 63 of the 86 other live ones, and was the 334th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →67 of the 356 studies in Heart Defects, Congenital with a site in United States are open now. Recruiting first, the newest first:
University of Nebraska · Sites in United States
Ages 1 mo–3 yrs
Le Bonheur Children's Hospital · Sites in United States
Ages 0 mo–12 mo
Carelon Research · Sites in United States
Ages 18+
Carelon Research · Sites in United States
Ages 18+
The Cleveland Clinic · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 7 Days to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
356 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 33 · Phase 3 25 · Phase 4 9
First in 1980; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 48 across the 184 interventional studies, 72 across the 167 observational. Of the 241 that completed or were terminated, 62 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 356 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with June Wu as lead sponsor.
June Wu has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
29 of the studies in Heart Defects, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04216927Phase 3Children's Hospital Medical Center, CincinnatiNO During CPB in Neonates to Reduce Risk of AKI | 2027-06-30 |
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT07559253University of Wisconsin, MadisonImplementation of an Accessible Healthcare Model (ACHD STRONG): Comparing Nurse and Physician Lead Healthcare Transition Education in a RE-AIM Framework | 2026-11-30 |
| NCT04236479Catherine BollardMesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP) | 2026-12 |
| NCT05849025Mayo ClinicA Study of Invasive Hemodynamic for MACHD Registry | 2026-12 |
Add all 29 to your calendar (.ics) → With an account.
Among the 356 studies in Heart Defects, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postoperative chylothorax is a serious complication after open heart surgery for pediatric patients with congenital heart disease (CHD). While it was thought to be mechanical injury to the thoracic duct, recent research demonstrated that there are intrinsically abnormal lung lymphatics in CHD patients, and after open heart surgery, the fluid shifts that occur overwhelms these abnormal lung lymphatics. As a result, postoperative chylothorax occurs. Propranolol has been found to be helpful in resolving postoperative chylothorax very quickly (9 days) in a subset of postoperative chylothorax patients (60%). However, it is not known why some patients respond and some do not. The investigators hypothesize that propranolol is safe to use in this patient population, and that certain clinical factors will predict propranolol response, but more importantly, some clinical factors can be optimize to allow more patients with postoperative chylothorax to respond to and benefit from propranolol. In order to improve the understanding of how propranolol works and to maximize benefit to patients, the investigators propose to perform a prospective, randomized, double-blind clinical trial to learn how to best use propranolol in patients with postoperative chylothorax.
This clinical trial will prospectively enroll eligible patients and randomize them to placebo or propranolol (1:1). This study will aim to enroll 50 patients, randomized to 25 placebo and 25 propranolol treatment. After patients have been consented, registered, and screened, they will be entered into the study. Participants will be randomized to placebo or propranolol in a 1:1 ratio. Randomization will be double-blinded, and each enrolled participant will be given a number and receive coded medication from the research pharmacy. Patients may undergo a screening MR lymphangiogram (MRL) prior to starting treatment. The criteria for an MRL will require that no additional sedation be given, and patient or parent/legal guardian consents to an MRL. Thus, only patients who are already sedated, or who will be able to undergo the MRL without sedation, and who opts in to the MRL will be eligible. Propranolol or placebo will be administered for 9 days after reaching the lowest effective goal dose not to exceed 2mg/kg/day, or maximum tolerated dose, after which the study groups will be unmasked.
Participants who have ≥80% reduction in volume of chylothorax drainage after 9 days of treatment and who received propranolol are identified as "responders". They will be taken off the study officially at this point as no more study interventions will be given. They will be tapered off of propranolol gradually as clinically indicated.
Participants who have ≥80% reduction in volume of chylothorax drainage but who received placebo will be the "natural history cohort". This will serve to demonstrate, as baseline, the percentage of participants who naturally resolve their chylothorax without intervention.
Patients who have \<80% reduction in chylothorax drainage and who received propranolol, will be categorized as initial "non-responders". They will be officially taken off the study.
Participants who have \<80% reduction in chylothorax drainage and who received placebo are considered a control group. They will be given propranolol for 9 days as a single-arm, open study and re-evaluated after a 9-day treatment. After 9 days at goal dosing, they will receive the same treatment as the responders and non-responders in the propranolol-treated group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
pleural triglyeride (TG) ≥ half of serum TG, or chylomicron positive
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo suspension will only have Ora-Blend
Drug: Placebo
Subjects will be randomized to receive 2mg/kg/day. Propranolol will be administered orally, either as a tablet or as a solution, in equal divided doses three times a day.
Drug: Propranolol Hydrochloride
Propranolol will be administered as tablets. Participants who are too young to swallow pills will be given propranolol solution.
Also known as: Propranolol, 2-Propanol, 1-[(1-methylethyl)amino]-3-(1- naphthalenyloxy)-, hydrochloride
Placebo suspension will only have Ora-Blend Medication Flavoring and Suspension Vehicle
Also known as: Ora-Blend
Daily heart rates recorded in flow chart and 1 hour after each dose
Safety outcome
Time frame: 24 days
Daily blood pressures recorded in flow chart and 1 hour after each dose
Safety outcome
Time frame: 24 days
Daily glucose levels
Safety outcome
Time frame: 24 days
Expected and unexpected AEs, per patient
Safety outcome
Time frame: 24 days
Days with documented chest tube (# days), CXR
Will also measure the daily output (volume) in the chest tube(s)
Time frame: 24 days
Initial volume of fluid drained (mL, mL/kg/day)
The volume at the initial day of postoperative chylothorax diagnosis
Time frame: Day 0
Days hospitalized
The length of hospital stay, from post-surgery to discharge
Time frame: 6 months
Thyroglobulin (TG) lymphocyte count
The TG count will be analyzed from the postoperative chylothorax fluid.
Time frame: 24 days
Pre-operative and post-operative echocardiogram anatomic findings for patients with 4-chamber hearts
This outcome will be reported as the percent of patients with normal LV function, normal RV function, and normal pulmonary artery pressure.
Time frame: Pre-operative and up to 24 days
Pre-operative and post-operative echocardiogram anatomic findings for patients with single ventricle (SV) physiology
This outcome will be reported as the percent of patients with normal ventricular function and normal pulmonary artery pressure.
Time frame: Pre-operative and up to 24 days
Percent of patients with Type 1 anatomy
Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype
Time frame: Day 0
Percent of patients with Type 2 anatomy
Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype
Time frame: Day 0
Percent of patients with Type 3 anatomy
Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype
Time frame: Day 0
Percent of patients with Type 4 anatomy
Screening MR lymphangiogram: An optional imaging study to define lymphatic anatomy subtype
Time frame: Day 0
Serum albumin
to be extracted from clinical lab results, if available
Time frame: 24 days
White Blood Cell (WBC) count
to be extracted from clinical lab results, if available
Time frame: 24 days
C-Reactive Protein (CRP)
to be extracted from clinical lab results, if available
Time frame: 24 days
Immunoglobulin level
to be extracted from clinical lab results, if available
Time frame: 24 days
AT3 titer
to be extracted from clinical lab results, if available
Time frame: 24 days
Protein S titer
to be extracted from clinical lab results, if available
Time frame: 24 days
Protein C titer
to be extracted from clinical lab results, if available
Time frame: 24 days
Hours on bypass during CHD surgery
The amount of time the participant was on bypass during heart surgery
Time frame: During surgery
Triglyceride level in chylothorax fluid
Triglyceride levels will be measured
Time frame: 24 days
Plan to share: No — The aggregate data can be shared. The plan is not to share individual participant data to protect their privacy.
Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Propranolol